within Pharmacolibrary.Drugs.D_Dermatologicals.D11A_OtherDermatologicalPreparations.D11AH08_Abrocitinib;

model Abrocitinib
  extends Pharmacolibrary.Drugs.ATC.D.D11AH08;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>D11AH08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Abrocitinib is an oral Janus kinase 1 (JAK1) inhibitor indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents. It is approved for clinical use in several regions, including the US and EU.</p><h4>Pharmacokinetics</h4><p>Reported from healthy adult subjects after oral administration of a single 200 mg dose in phase I studies.</p><h4>References</h4><ol><li><p>Wang, X, et al., &amp; Malhotra, BK (2024). Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals. <i>European journal of drug metabolism and pharmacokinetics</i> 49(3) 367–381. DOI:<a href=\"https://doi.org/10.1007/s13318-024-00893-5\">10.1007/s13318-024-00893-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38554232/\">https://pubmed.ncbi.nlm.nih.gov/38554232</a></p></li><li><p>Deeks, ED, &amp; Duggan, S (2021). Abrocitinib: First Approval. <i>Drugs</i> 81(18) 2149–2157. DOI:<a href=\"https://doi.org/10.1007/s40265-021-01638-3\">10.1007/s40265-021-01638-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34807428/\">https://pubmed.ncbi.nlm.nih.gov/34807428</a></p></li><li><p>Wang, EQ, et al., &amp; Malhotra, BK (2022). Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites. <i>Journal of clinical pharmacology</i> 62(4) 505–519. DOI:<a href=\"https://doi.org/10.1002/jcph.1980\">10.1002/jcph.1980</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34637151/\">https://pubmed.ncbi.nlm.nih.gov/34637151</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Abrocitinib;
